Deutsche Medizinische Wochenschrift最新文献

[Measures for diarrhoea during chemotherapy and targeted therapy]. [化疗和靶向治疗期间的腹泻对策]。

IF 0.6 4区医学

Deutsche Medizinische Wochenschrift Pub Date : 2024-04-24 DOI: 10.1055/a-2204-5395

Katharina Sommer, S. Wulf, Julia Gallwas

引用次数: 0

[Transition in sickle cell disease - recommendations of the transition initiative sickle cell disease]. [镰状细胞病的过渡--镰状细胞病过渡倡议的建议]。

IF 0.6 4区医学

Deutsche Medizinische Wochenschrift Pub Date : 2024-04-24 DOI: 10.1055/a-2252-8113

Janine Böll, F. Alashkar, Carmen Aramayo-Singelmann, Anette Hoferer, Andrea Jarisch, Haytham Kamal, Lena Oevermann, Michaela Schwarz, Holger Cario

{"title":"[Transition in sickle cell disease - recommendations of the transition initiative sickle cell disease].","authors":"Janine Böll, F. Alashkar, Carmen Aramayo-Singelmann, Anette Hoferer, Andrea Jarisch, Haytham Kamal, Lena Oevermann, Michaela Schwarz, Holger Cario","doi":"10.1055/a-2252-8113","DOIUrl":"https://doi.org/10.1055/a-2252-8113","url":null,"abstract":"Sickle cell disease is a rare, but complex multi-systemic disorder with high need of interdisciplinary and specialized care and new structural requirements. Besides care of those chronically sick patients, transition process is a vulnerable phase which highly influences further treatment. To make matters worse, patients often have migration background with subsequent communication problems. A national guidance for a standardized transition process is lacking in Germany. In context of a structured consensus process, the \"transition initiative sickle cell disease\" developed specific recommendations for a structured transition of sickle cell patients on the basis of the S3 transition guideline of the DGfTM. These recommendations should improve this vulnerable process in this complex disease to ensure adequate further treatment and to avoid acute and chronic complications but also mental, social or job-related issues. Besides improvement of quality of life, medical treatment and survival, health economic aspects arise. Documents were developed to support and facilitate the transition process and are available under www.sichelzellkrankheit.info/transition/.","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140659318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Intraosseous vascular access - step by step]. [骨内血管通路--循序渐进]。

IF 0.6 4区医学

Deutsche Medizinische Wochenschrift Pub Date : 2024-04-24 DOI: 10.1055/a-2208-7398

Andrea Greulich, Jens Tiesmeier, Andreas Breuer-Kaiser

引用次数: 0

[Invasive fungal infections: Challenges and recent developments]. [侵袭性真菌感染：挑战与最新进展]。

IF 0.6 4区医学

Deutsche Medizinische Wochenschrift Pub Date : 2024-04-24 DOI: 10.1055/a-2128-7324

Marylyn Addo

引用次数: 0

[Mucormycosis in the time of COVID-19: risks and challenges]. [COVID-19 时代的粘孢子菌病：风险与挑战]。

IF 0.6 4区医学

Deutsche Medizinische Wochenschrift Pub Date : 2024-04-24 DOI: 10.1055/a-2139-3902

Danila Seidel, Ertan Sal, Julia A. Nacov, O. Cornely, Oliver Kurzai

{"title":"[Mucormycosis in the time of COVID-19: risks and challenges].","authors":"Danila Seidel, Ertan Sal, Julia A. Nacov, O. Cornely, Oliver Kurzai","doi":"10.1055/a-2139-3902","DOIUrl":"https://doi.org/10.1055/a-2139-3902","url":null,"abstract":"The first patients positive for SARS-CoV-2 were registered in December 2019. In March 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a global pandemic, the beginning of a worldwide health crisis that revealed numerous medical challenges for healthcare systems and pandemic emergency strategies.Among these challenges, mucormycosis, a typically rare fungal infection, gained global attention. With an average global incidence of about 2 per 1 million people, mucormycosis is considered a very rare disease, an opportunistic infection mostly affecting the lungs or skin and soft tissues in immunocompromised patients. Poorly controlled diabetes mellitus is one of the leading risk factors for rhino-orbital mucormycosis. Countries with a high prevalence of diabetes and limited healthcare resources have higher mucormycosis rates, with India and Pakistan being among the nations with particularly high incidences.During the second wave of the COVID-19 pandemic in India, mucormycosis rates surged dramatically within a few weeks, with over 47,500 cases of COVID-19-associated mucormycosis (CAM) reported between May and August 2021. Mucormycosis is characterized by a high mortality rate of up to 90%, especially when the diagnosis is delayed, and treatment commences late. There were concerns about a potentially global threat.In this article, we explore the risk factors and mechanisms leading to this viral-fungal coinfection. We present global distribution patterns, clinical presentation, and challenges in the diagnosis and treatment of COVID-19-associated mucormycosis.","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140659807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Diagnostic approaches for invasive mycoses: what's hot?] [侵袭性真菌病的诊断方法：什么是热点？］

IF 0.6 4区医学

Deutsche Medizinische Wochenschrift Pub Date : 2024-04-24 DOI: 10.1055/a-2133-4826

Cornelia Lass-Flörl

引用次数: 0

[Innovative therapies for treatment of invasive fungal diseases]. [治疗侵袭性真菌疾病的创新疗法]。

IF 0.6 4区医学

Deutsche Medizinische Wochenschrift Pub Date : 2024-04-24 DOI: 10.1055/a-2132-9240

Sibylle C Mellinghoff, Oliver A Cornely, Parvin Mammadova, R. Sprute, Jannik Stemler

{"title":"[Innovative therapies for treatment of invasive fungal diseases].","authors":"Sibylle C Mellinghoff, Oliver A Cornely, Parvin Mammadova, R. Sprute, Jannik Stemler","doi":"10.1055/a-2132-9240","DOIUrl":"https://doi.org/10.1055/a-2132-9240","url":null,"abstract":"Invasive fungal diseases (IFD) are difficult to treat and pose a significant threat to immunocompromised individuals. Current antifungal agents face limitations, including antifungal resistance and adverse effects. This review aims to give a comprehensive overview of emerging treatment strategies.Novel drugs in development are Ibrexafungerp, an orally available triterpenoid inhibiting glucan synthesis, and Rezafungin representing the echinocandins with extended half-life and improved tissue penetration, both recently licensed for certain indications. Fosmanogepix targets glycosylphosphatidylinositol biosynthesis, while Olorofim, an orotomide, inhibits fungal nucleic acid synthesis, both currently assessed in advanced clinical trials.Immunotherapeutic approaches include immune checkpoint inhibitors to enhance immune response in immunosuppressed individuals and fungal-specific allogeneic CAR-T cell therapy. For prophylactic purpose in high-risk populations to develop IFD, monoclonal antibodies against different virulence factors of Candida spp. have been discovered but are not yet seen in clinical trials. Vaccines against distinct fungal antigens as well as pan fungal vaccines to prevent IFD are under development in preclinical stages, notably for Candida spp., Cryptococcus spp., and Aspergillus spp., however, their clinical value is still discussed.In summary, major advances to treat IFD have been observed, but challenges for their establishment in the clinical routine persist.","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140665751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Gastrointestinal tumour prevention strategies]. [胃肠道肿瘤预防策略]。

IF 0.6 4区医学

Deutsche Medizinische Wochenschrift Pub Date : 2024-04-01 DOI: 10.1055/a-2060-2225

Michael Quante, Susann Schütte

{"title":"[Gastrointestinal tumour prevention strategies].","authors":"Michael Quante, Susann Schütte","doi":"10.1055/a-2060-2225","DOIUrl":"https://doi.org/10.1055/a-2060-2225","url":null,"abstract":"Over the past few decades, substantial advancements have been achieved in the early detection and treatment of gastrointestinal oncological diseases. The survival rates of patients have significantly improved due to the expansion and enhancement of therapeutic and diagnostic options, leading to modifications in (neo-)adjuvant, perioperative, and palliative strategies, as well as the advent of personalized molecular therapy. Noteworthy progress has also been observed in primary, secondary, and tertiary prevention domains.Despite these advancements, gastrointestinal tumours continue to be a global health burden, with approximately 4 million new cases diagnosed annually. These constitute over a quarter of all tumour cases, with nearly one-third of all global tumour-related mortalities attributed to gastrointestinal tumours.Emerging evidence implicates aberrant differentiation of stem or progenitor cells in the pathogenesis of gastrointestinal tumour diseases. A confluence of clinically recognized risk factors, including high-fat diet, bile acid, microbiome alterations, and host factors, can instigate chronic inflammation. This disrupts stem cell homeostasis and precipitates malignant transformation. Consequently, environmental inflammation emerges as a critical risk factor warranting consideration in clinical cancer prevention and surveillance strategies.This review encapsulates the current understanding and recommendations in the prevention of selected gastrointestinal tumours, aiming to facilitate their integration into clinical practice. It underscores the need for continued research to further refine diagnostic and therapeutic strategies and improve patient outcomes.","PeriodicalId":11370,"journal":{"name":"Deutsche Medizinische Wochenschrift","volume":null,"pages":null},"PeriodicalIF":0.6,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140780738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Updated guidelines for cardiac patients with diabetes - Pragmatic diagnostic and therapeutic algorithm]. [糖尿病心脏病患者的最新指南--实用诊断和治疗算法]。

IF 0.6 4区医学

Deutsche Medizinische Wochenschrift Pub Date : 2024-04-01 DOI: 10.1055/a-2226-0683

J. Gollmer, A. Zirlik, Heiko Bugger

引用次数: 0

[Diagnosis of acute coronary syndrome]. [急性冠状动脉综合征的诊断]。

IF 0.6 4区医学

Deutsche Medizinische Wochenschrift Pub Date : 2024-04-01 DOI: 10.1055/a-2163-2586

Niklas Thießen, Renate Schnabel

引用次数: 0